Prognosis Value of the Neuronal Damage in Early Multiple Sclerosis
Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
In this study the investigators will use PET and 11C-Flumazenil to visualize and quantify
neuronal injury in the cortex and the deep gray matter of Multiple Sclerosis patients at an
early stage. The investigators will follow up patients to determine the prognostic value of
this neuronal injury.